{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:05:54Z","timestamp":1778864754796,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.vaccine.2019.09.034","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T01:50:07Z","timestamp":1572659407000},"page":"B65-B75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S2","title":["ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7704-0527","authenticated-orcid":false,"given":"Kaatje","family":"Bollaerts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Ledent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"de Smedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1685-1478","authenticated-orcid":false,"given":"Daniel","family":"Weibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne-Dorthe","family":"Emborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Danieli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talita","family":"Duarte-Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-7826","authenticated-orcid":false,"given":"Consuelo","family":"Huerta-Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-8605","authenticated-orcid":false,"given":"Elisa","family":"Mart\u00edn-Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino","family":"Picelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Tramontan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-2388","authenticated-orcid":false,"given":"Miriam","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Bauchau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.09.034_b0005","doi-asserted-by":"crossref","first-page":"B1","DOI":"10.1016\/j.vaccine.2019.07.081","article-title":"Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines","volume":"38","author":"Sturkenboom","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.034_b0010","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/pds.3636","article-title":"Balancing benefit and risk of medicines: a systematic review and classification of available methodologies","volume":"23","author":"Mt-Isa","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.09.034_b0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1524-4733.2010.00725.x","article-title":"A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group","volume":"13","author":"Guo","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2019.09.034_b0020","unstructured":"Innovative Medicines Initiative PROTECT project 2010. Available from: http:\/\/www.imi-protect.eu\/index.shtml."},{"key":"10.1016\/j.vaccine.2019.09.034_b0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/pds.3958","article-title":"Recommendations for benefit-risk assessment methodologies and visual representations","volume":"25","author":"Hughes","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.09.034_b0030","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.09.034_b0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.2323","article-title":"The Food and Drug Administration's post-licensure rapid immunization safety monitoring program: strengthening the federal vaccine safety enterprise","volume":"21","author":"Nguyen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.09.034_b0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jval.2015.12.016","article-title":"Multiple criteria decision analysis for health cared decision making\u2013emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"Marsh","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2019.09.034_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","article-title":"Multiple criteria decision analysis for health care decision making\u2013an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"Thokala","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2019.09.034_b0050","series-title":"Benefit-risk apraisal of mdicines: a systematic approach to decision-making","author":"Mussen","year":"2009"},{"key":"10.1016\/j.vaccine.2019.09.034_b0055","doi-asserted-by":"crossref","first-page":"B22","DOI":"10.1016\/j.vaccine.2019.07.039","article-title":"ADVANCE system testing: can coverage of pertussis vaccination be estimated in EU countries using electronic health data: an example","volume":"38","author":"Emborg","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.034_b0060","doi-asserted-by":"crossref","first-page":"B31","DOI":"10.1016\/j.vaccine.2019.08.078","article-title":"ADVANCE system testing: vaccine benefit studies by using multi-country electronic health data: An example on pertussis vaccination","volume":"38","author":"Htar","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.034_b0065","doi-asserted-by":"crossref","first-page":"B38","DOI":"10.1016\/j.vaccine.2019.06.040","article-title":"ADVANCE system testing: can safety studies be conducted using electronic health data: an example with pertussis vaccination?","volume":"38","author":"Weibel","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.034_b0070","doi-asserted-by":"crossref","first-page":"B8","DOI":"10.1016\/j.vaccine.2020.01.100","article-title":"ADVANCE database characterization and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of vaccinations","volume":"38","author":"Sturkenboom","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.034_b0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2307\/2533328","article-title":"Relative incidence estimation from case series for vaccine safety evaluation","volume":"51","author":"Farrington","year":"1995","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2019.09.034_b0080","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1542\/peds.2004-2759","article-title":"Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998\u20132001","volume":"116","author":"Bisgard","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.09.034_b0085","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cid\/ciw051","article-title":"Protective effect of contemporary pertussis vaccines: a systematic review and meta-analysis","volume":"62","author":"Fulton","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.034_b0090","first-page":"73","article-title":"Pertussis \u2013- United States, 1997\u20132000","volume":"51","author":"Zanardi","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.09.034_b0095","series-title":"a language and environment for statistical computing","author":"Development Core","year":"2013"},{"key":"10.1016\/j.vaccine.2019.09.034_b0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.vaccine.2019.09.034_b0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2307\/2683591","article-title":"LOWESS: A program for smoothing scatterplots by robust locally weighted regression","volume":"35","author":"Cleveland","year":"1981","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2019.09.034_b0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1586\/14760584.2016.1107480","article-title":"Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males","volume":"15","author":"Marcelon","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.09.034_b0115","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/pds.3676","article-title":"Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology","volume":"23","author":"Hallgreen","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.09.034_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/pds.4419","article-title":"Methodology for computing the burden of disease of adverse events following immunization","author":"McDonald","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:33Z","timestamp":1759401333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19312435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":24,"alternative-id":["S0264410X19312435"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}